Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

What this episode covers

For the complete activity, including supporting material, please visit https://www.peervoice.com/CFH860. Presented by Javier Cortés, MD, PhD and Laura Huppert, MD. Learning Objectives: Recall the results of clinical trials evaluating TROP2-directed antibody-drug conjugates (ADCs) as monotherapy or in combination with a PD-1 inhibitor in frontline treatment settings of HR+/HER2- or triple-negative metastatic breast cancer (TNBC); Assess the potential clinical impact of these data, including patient populations included in trials and how these relate to patients seen in the real-world clinic..

Distinct summary based on available episode metadata or transcript content.